Skip to main content
Clinical Trials/JPRN-UMIN000029890
JPRN-UMIN000029890CompletedPhase 2

Phase 2 Study of imatinib in c-kit mutant Advanced Melanoma - MM_CKIT

Keio University0 sites21 target enrollmentStarted: November 8, 2017Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
21

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Exclusion Criteria The subject must be excluded from participation in the trial if the subject: 1) Has known history of Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA is detected). 2) Has known history of human immunodeficiency virus (HIV). 3) Has active infection, clinically significant cardiac disease, including unstable angina and arrhythmia, psychiatric disorder. 4) Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

Investigators

Similar Trials